Taro Pharmaceutical Industries (NYSE:TARO) Coverage Initiated at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO) in a research report issued on Friday. The firm set a “strong-buy” rating on the stock.

Taro Pharmaceutical Industries Trading Down 0.0 %

Taro Pharmaceutical Industries stock opened at $42.73 on Friday. The firm has a 50-day moving average of $42.46 and a 200-day moving average of $41.88. The firm has a market cap of $1.61 billion, a P/E ratio of 29.67 and a beta of 0.56. Taro Pharmaceutical Industries has a 1-year low of $32.67 and a 1-year high of $45.76.

Taro Pharmaceutical Industries (NYSE:TARO) last posted its earnings results on Monday, May 20th. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.12. The company had revenue of $164.94 million during the quarter, compared to analyst estimates of $156.10 million. Taro Pharmaceutical Industries had a net margin of 8.56% and a return on equity of 3.75%.

Institutional Trading of Taro Pharmaceutical Industries

Institutional investors and hedge funds have recently bought and sold shares of the stock. LRI Investments LLC purchased a new stake in Taro Pharmaceutical Industries in the first quarter worth about $84,000. PenderFund Capital Management Ltd. purchased a new stake in Taro Pharmaceutical Industries in the fourth quarter worth about $92,000. FNY Investment Advisers LLC purchased a new stake in Taro Pharmaceutical Industries in the fourth quarter worth about $105,000. BNP Paribas Financial Markets lifted its holdings in Taro Pharmaceutical Industries by 77.9% in the first quarter. BNP Paribas Financial Markets now owns 4,107 shares of the company’s stock worth $174,000 after buying an additional 1,799 shares during the period. Finally, SG Americas Securities LLC lifted its holdings in Taro Pharmaceutical Industries by 24.5% in the fourth quarter. SG Americas Securities LLC now owns 4,673 shares of the company’s stock worth $195,000 after buying an additional 921 shares during the period. 91.40% of the stock is currently owned by hedge funds and other institutional investors.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.